您当前位置: 首页  师资队伍  教师名单  教授

麻楠

发布时间:2023-03-24 发布单位:药学院

1、个人简介:

麻楠,理学博士,研究员,硕士研究生导师。2011年毕业于中国药科大学,获学士学位;2016年毕业于中国药科大学药物化学专业(与中国科学院广州生物医药与健康研究院联合培养),获博士学位;同年进入暨南大学从事博士后科研工作。2020年于中国中医科学院青蒿素研究中心进行科研工作。20219月经暨南大学高层次人才引进,加入暨南大学药学院。研究方向涉及天然产物全合成、药物化学及化学生物学,近年来主要基于分子探针、蛋白质组学等技术手段围绕活性分子开展靶标识别及鉴定研究。目前,已主持国家及省部级科学基金项目4项,申请专利2项,其中1项已授权。已在LancetJ Am Chem SocJ Clin InvestPharmacol TherNat Prod Rep等国际顶级权威期刊发表学术论著20余篇,其中以第一作者/通讯作者(含共同)发表SCI论文13篇。

2、讲授课程:《有机化学》、《科研论文写作》

3、研究方向:

1)药物活性分子靶标识别与鉴定

2)天然生物活性分子的全合成及结构修饰研究

4、代表性科研项目:

1)国家自然科学基金青年基金项目(81803389),基于双重光亲和标记策略的钩吻毒性成分作用靶标研究(2019/01-2021/1221万,主持)

2)广东省自然科学基金博士启动―纵向协同项目(2018A030310651),双重光亲和标记技术确证14-羟基钩吻素已的毒性作用靶标研究(2018/05-2021/0410万,主持)

3)中国博士后科学基金(2017M622923),基于双重光亲和标记的14-羟基钩吻素己毒性靶标研究(2017/03-2018/125万,主持)

4)广州市基础与应用基础研究专题(SL2022A04J00501),基于细胞热转变分析的天然产物callistrilon E抗耐菌靶标及机制研究,(2023/04 2025/035万,主持)

5)国家自然科学基金面上项目(21877050),新型最小化分子链用于非可逆药物分子的靶标确证研究(2019/01-2022/1267万,参与)

6)国家自然科学基金面上项目(21472191),Flueggines A and B的全合成研究(2015/01-2018/1290万,参与)

5、代表性论文和专著:

[1] Ke Cheng, Junyang Qi, Xiaojie Ren, Jie Zhang, Huangxu Li, Hanyue Xiao, Rui Wang, Zhiyang Liu, Lingkuan Meng, Nan Ma*, Hongyan Sun*. Developing Isoxazole as a Native Photo-Cross-Linker for Photoaffinity Labeling and Chemoproteomics. Angew Chem Int Ed Engl., 2022, 21, 61(47). (corresponding author, IF= 16.823)

[2] Dandan Liu#, Piao Lu#, Liwei Gu, Qian Zhang, Peng Gao, Yongping Zhu, Xiao Chen, Qiuyan Guo, Junzhe Zhang, Nan Ma*, Jigang Wang*, Celastrol exerts a neuroprotective effect by directly binding to HMGB1 protein in cerebral ischemia-reperfusion. J Neuroinflamm., 2021, 18(1): 118. (corresponding author, IF = 9.589)

[3] Hai-Ning Lyu#, Nan Ma#, Yuqing Meng#, Xing Zhang, Yin-Kwan Wong, Chengchao Xu*, Fulong Liao, Tingliang Jiang, Youyou Tu*, Jigang Wang*. Study towards improving artemisinin-based combination therapies. Nat Prod Rep., 2021, 38(7): 1243-1250. (co-first author, IF = 15.111)

[4] Yuqing Meng#, Nan Ma#, Hai-Ning Lyu#, Yin Kwan Wong, Xing Zhang, Yongping Zhu, Peng Gao, Peng Sun, Yali Song, Lizhu Lin*, Jigang Wang*. Recent pharmacological advances in the repurposing of artemisinin drugs. Med Res Rev., 2021, 41(6): 31563181. (co-first author, IF = 12.944)

 [5] Nan Ma, Jun Hu, Zhimin Zhang, Wenyan Liu, Minhao Huang, Youlong Fan, Xingfeng Yin, Jiang Wang*, Ke Ding*, Wencai Ye*, Zhengqiu Li*. 2H-Azirine-based Reagents for Chemoselective Bioconjugation at Carboxyl Residues inside Live Cells.J Am Chem Soc., 2020, 142(13): 6051–6059. (IF = 16.383)

[6]Nan Ma, Ziyue Zhang, Fulong Liao, Tingliang Jiang, Youyou Tu*. The birth of artemisinin. Pharmacol Ther., 2020, 216: 107658. (IF = 13.4)

[7] Xiao Chen#, Yutong Wang#, Nan Ma#, Jing Tian, Yurou Shao, Bo Zhu, Yin Kwan Wong, Zhen Liang, Chang Zou, Jigang Wang*. Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification. Signal Transduct Target Ther.,2020, 5(1): 72. (co-first author, IF = 38.104)

[8] Shengnan Shen#, Qiwen Liao#, Ming Lyu#, Yin-Kwan Wong, Xing Zhang, Jing Zhou*, Nan Ma*, Jigang Wang*. The potential of artemisinins as anti-obesity agents via modulating the immune system. Pharmacol Ther., 2020, 216: 107696. (corresponding author, IF = 13.4)

[9] Nan Ma, Zhi-Min Zhang, Jun-Seok Lee, Ke Cheng, Ligen Lin, Dong-Mei Zhang, Piliang Hao*, Ke Ding*, Wen-Cai Ye*, Zhengqiu Li*. Affinity-based Protein Profiling Reveals Cellular Targets of Photoreactive Anticancer Inhibitors. ACS Chem Biol., 2019, 14(12), 2546–2552. (IF = 4.634)

 [10] Nan Ma#, Yiwu Yao#, Bing-Xin Zhao, Ying Wang, Wen-Cai Ye*, Sheng Jiang*. Total synthesis of securinega alkaloids (-)-norsecurinine, (-)-niruroidine and (-)-flueggine A. Chem. Commun., 2014, 50: 9284–9287. (IF = 6.065)

6、联系方式: